1444283824
Investment Research Radio

Advertise on podcast: Investment Research Radio

This podcast has
64 episodes
Language
English
Explicit
No
Date created
2018/11/22
Latest episode
2026/11/13
Average duration
20 min.
Release period
12 days

Description

Investment Research Radio interviews the most exciting up and coming companies both private and publicly traded. While being sector agnostic there is a focus on clean technologies, blockchain and being on top of the major trends which are changing the world around us.

Unlock Investment Research Radio podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Investment Research Radio podcast


BiRed Imaging with Dr. Satish Kandlikar CEO and Dr. Prad Phatak CMO
2026/11/13
BiRed Imaging: Exploring a New Approach to Breast Cancer Detection Through Infrared Imaging and AI What if infrared imaging and artificial intelligence could offer clinicians a new source of information to support breast cancer detection and assessment? On this episode of Investment Research Radio, we speak with Professor Satish Kandlikar, CEO and Co founder of BiRed Imaging, and Dr. Pradyumna ("Prad") Phatak, Chief Medical Officer, about the development of an innovative approach to breast cancer detection combining infrared imaging, mathematical modeling and artificial intelligence. BiRed Imaging is developing a noninvasive imaging technology designed to identify and localize potential breast tumors by analyzing the body's natural thermal signatures. The system combines infrared camera measurements with patient specific digital breast models and numerical heat transfer simulations to help assess the presence, size and location of potential abnormalities. The technology offers an exciting avenue of research with the potential to complement existing breast imaging approaches and provide additional diagnostic information. Its noninvasive nature, lack of radiation exposure and potential application for women with dense breast tissue make it an interesting area of emerging medical technology. In this conversation, we explore: The origins of BiRed Imaging and the research that inspired its development. How infrared imaging and mathematical modeling can identify thermal patterns potentially associated with breast tumors. How the technology aims to determine the potential size and location of tumors. The limitations and challenges of current breast cancer screening approaches and the opportunity for complementary technologies. Early research findings and the importance of continued clinical validation. The potential application of the technology for women with dense breast tissue. The role of artificial intelligence and computational modeling in advancing breast imaging. Regulatory considerations, clinical studies and the pathway toward commercialization. The broader opportunity to make breast cancer screening more accessible, comfortable and informative. Professor Kandlikar brings extensive engineering and research experience to the development of the technology, while Dr. Phatak contributes important clinical and medical perspectives on breast cancer detection and patient care. BiRed Imaging is pursuing a promising approach that could contribute to the future of breast imaging by providing clinicians with another tool to investigate and assess potential abnormalities. While further research and clinical validation will be important in establishing its capabilities, the technology represents an exciting opportunity to explore new possibilities in breast cancer detection. Learn more about BiRed Imaging: https://www.biredimaging.com/ Thank you to Professor Satish Kandlikar and Dr. Pradyumna Phatak for joining Investment Research Radio.
Nanochon With CEO Dr. Ben Holmes
2026/11/02
Nanochon with CEO Dr. Ben Holmes | 3D-Printed Implants and the Future of Cartilage Repair In this episode of Investment Research Radio, Ray Crowley sits down with Dr. Ben Holmes, Co-Founder and CEO of Nanochon, a medical technology company developing next generation orthopedic implants designed to repair damaged cartilage and potentially offer an alternative to more invasive joint replacement procedures. Nanochon is developing Chondrograft, a synthetic, 3D printed implant designed to restore cartilage function in patients suffering from focal cartilage defects and early-stage osteoarthritis. Using proprietary biomaterials and advanced manufacturing techniques, the technology aims to address a significant gap in orthopedic care, particularly for younger and active patients who may not be ideal candidates for total knee replacement. Dr. Holmes discusses the origins of Nanochon, the science behind its implant technology, and the journey from university research and biomedical engineering to clinical development and commercialization. We explore the company's preclinical research, including animal studies, its progression into first-in-human clinical trials, and the regulatory and clinical milestones required to bring an innovative orthopedic implant to market. We also discuss the broader market opportunity for cartilage repair, the challenges of building and financing a medical device company, and Nanochon's longer-term vision for expanding its technology across additional joints and orthopedic applications. Topics covered include: The founding story behind Nanochon and the origins of its technology. Chondrograft™ and the science of synthetic, 3D-printed cartilage implants. Biomaterials, advanced manufacturing, and tissue integration. Preclinical research and animal study results. First-in-human clinical development and regulatory milestones. The limitations of existing cartilage repair treatments. The commercial opportunity in orthopedic implants and joint preservation. Fundraising, commercialization, and the future of Nanochon. Learn more about Nanochon: https://nanochon.com/ Guest: Dr. Ben Holmes, Co-Founder and CEO, Nanochon Host: Ray Crowley, Investment Research Radio
LifePlus with CEO Alodeep Sanyal
2026/10/29
LifePlus: LifeLeaf Watch, Non-Invasive Health Monitoring and the Future of Wearables In this episode of Investment Research Radio, we explore LifePlus and its upcoming LifeLeaf smartwatch, a wearable designed to provide blood sugar and blood pressure trends from the wrist without needles or a traditional blood pressure cuff. LifePlus combines optical sensing, signal processing, and artificial intelligence to interpret physiological signals throughout everyday life. Its clinical research includes studies involving more than 70,000 paired readings across seven clinical sites, with findings published in peer reviewed journals including Diabetes, Diabetes Technology & Therapeutics, and the Journal of Hypertension. The company's research has also been presented at major scientific meetings, including the American Diabetes Association and the American Heart Association. We discuss the science behind LifeLeaf, the challenges of non invasive physiological monitoring, and how LifePlus is translating years of research and development into a consumer wearable. With its planned retail launch and Kickstarter campaign fast approaching, we also explore the company's commercialization strategy, distribution opportunities, and the potential for wearable technology to give consumers greater insight into how daily habits affect their health. Learn more: https://www.lifeplus.ai/
Nutromics With CEO Peter Vranes
2026/10/28
Investment Research Radio: Nutromics — Precision Antibiotic Dosing and the Future of Wearable Biosensing In this episode of Investment Research Radio, we explore Nutromics and its innovative wearable microneedle technology designed to transform precision medicine and continuous molecular monitoring. Nutromics' first product focuses on vancomycin, a powerful antibiotic widely used in hospitals to treat serious infections, including MRSA and sepsis. Because vancomycin has a narrow therapeutic window, clinicians must carefully balance effective dosing against the risk of toxicity, including kidney injury. Nutromics is developing a wearable sensor that continuously measures drug concentrations in the fluid beneath the skin, potentially helping clinicians make faster, more informed dosing decisions while reducing reliance on repeated blood draws. We discuss the clinical development underway, the potential benefits for hospital workflows and patient care, and the significance of the FDA granting the company's Vancomycin Therapeutic Drug Monitoring Patch Breakthrough Device Designation in September 2026. The designation supports regulatory engagement but does not constitute FDA marketing approval. Beyond antibiotic dosing, we explore Nutromics' longer-term vision for its Lab-on-a-Patch technology: wearable microneedle sensors capable of measuring multiple drugs and biomarkers simultaneously. Future applications could include monitoring indicators associated with sepsis, kidney injury, inflammation, and cardiovascular disease. Join us for a conversation about precision dosing, clinical innovation, and the potential for continuous, multi-analyte biosensing to change how hospitals monitor patients and manage treatment. Learn more: https://www.nutromics.com/
Purecore Metals With CEO Peter Berdusco
2026/10/26
Purecore Metals: A New Critical Minerals Story | Peter Berdusco, Founder & CEO In this five-minute episode of Investment Research Radio, I sit down with Peter Berdusco, Founder and CEO of Purecore Metals, a newly listed Canadian mining junior trading on the Canadian Securities Exchange (CSE: PURE), the OTCQB (OTCQB: PPURF) and the Frankfurt Stock Exchange (FSE: J8Y). Peter shares the story behind Purecore's inception, its focus on critical minerals including uranium and copper, and its exploration properties in Saskatchewan and British Columbia. We discuss the company's early development as a public company and its opportunity to participate in growing demand for nuclear energy, electrification and critical mineral supply. This is the first in a planned series of short, five minute conversations with founders and executives building emerging companies. Learn more: https://purecoremetals.com/
Skuvent With CEO Maunark Patel
2026/10/22
In this episode of Investment Research Radio, Ray Crowley speaks with Maunark Patel, Co-Founder and CEO of Skuvent, about the operational challenges medical device manufacturers face managing inventory, implants, and surgical equipment across warehouses, sales representatives, hospitals, and operating rooms. The conversation explores how Skuvent is addressing gaps in medical device field operations, including inventory tracking, consignment management, surgical case coordination, product transfers, expiration monitoring, audits, and integration with existing ERP and CRM systems. Maunark shares the story behind Skuvent, the problems the company aims to solve for medical device manufacturers, and the broader opportunity to improve visibility, accountability, and efficiency across complex medical device supply chains. We also discuss the competitive landscape, commercialization strategy, and Maunark's vision for the company's future. Join us for a conversation about the business of medical technology, the operational challenges facing device manufacturers, and the opportunity to modernize how medical devices move from the warehouse to the point of care. https://www.skuvent.com
Persperion with CEO Dr. Lu Yin
2026/10/19
What if glucose monitoring could be done without needles, using sweat sensing technology instead? In this episode of Investment Research Radio, I speak with Lu Yin, CEO and Co-Founder of Persperion, a company developing finger touch based sweat sensing technology with an initial focus on non-invasive glucose monitoring. We discuss the science behind Persperion's approach, the challenges of developing accurate non-invasive biosensors, and the potential to make health monitoring more accessible and convenient. We also explore the broader opportunity for sweat-based diagnostics and how advances in sensing technology could open the door to monitoring additional biomarkers in the future. As Persperion advances its technology toward clinical validation and commercialization, we discuss the development milestones, regulatory considerations, and market opportunities involved in bringing a new medical technology to patients. Tune in to hear Lu's perspective on building a deep technology company and the future of non invasive diagnostics. https://persperion.com/
WearbleDose with CEO John Sanwo
2026/10/15
In this episode of Investment Research Radio, Ray Crowley speaks with John Sanwo, Founder and CEO of WearableDose, about the company's development of precision radiation detection technology. WearableDose is developing wearable radiation sensing technology designed to support radiation monitoring and safety across applications such as healthcare, oncology, defense, aerospace and other environments where radiation exposure is a concern. Ray and John discuss the technology behind WearableDose, the challenges of developing wearable radiation detection systems, potential applications across different industries, and the company's journey toward commercialization. The conversation explores the growing role of advanced sensing technologies in improving radiation awareness, monitoring and safety for people working in environments where exposure matters. Tune in to learn more about WearableDose, its technology and John's vision for the future of wearable radiation detection. https://wearabledose.com/
NeuroDyne with CEO Dr. Mark Myers
2026/10/13
NeuroDyne with CEO Dr. Mark Myers | Investment Research Radio In this episode of Investment Research Radio, Ray Crowley speaks with Dr. Mark Myers, CEO and CTO of NeuroDyne, about the company's work in wearable electroencephalography (EEG) technology and its development of a wearable EEG cap designed to measure brain activity. Dr. Myers discusses the technology behind NeuroDyne's approach, its potential applications in neurological monitoring and healthcare, and the company's progress toward FDA Class II clearance. We explore the challenges of bringing innovative neurotechnology to market, the potential for future product iterations and applications, and the opportunities for wearable brain monitoring as neuroscience and medical technology continue to advance. Tune in to learn more about NeuroDyne's technology, its development journey, and Dr. Myers' vision for the future of wearable EEG.   https://www.neurodyneinc.com/
D&P Bioinnovations With CEO Dr. Derek Dashti
2026/10/08
Derek Dashti, Founder of D&P Bioinnovations | Rebuilding Damaged Tissue From Within In this episode of Investment Research Radio, I speak with Derek Dashti, founder of D&P Bioinnovations, about a potentially transformative approach to regenerative medicine. D&P Bioinnovations is developing an implantable, bioresorbable medical technology designed to help the body regenerate damaged tissue rather than simply repair or replace it. The company's approach combines engineered biomaterials with biological signals derived from stem cells to create an environment that can encourage the body's own cells to rebuild damaged tissue. The company's initial focus is one of the most difficult areas of tissue repair: the esophagus. Severe damage caused by conditions such as cancer can require highly invasive reconstructive procedures, sometimes involving the use of another part of the patient's body to replace the damaged esophagus. D&P's approach is aimed at something fundamentally different: using a temporary implant to support the body's own regenerative processes and potentially restore the tissue from within. What makes the science so interesting is the possibility that the technology could extend beyond a single organ or disease. If the underlying regenerative approach can be successfully translated into human therapies, it could have applications across a range of damaged tissues. Derek and I discuss the science behind the technology, what led him to pursue regenerative medicine, the challenges of moving from laboratory research toward clinical applications, and where he believes this technology could ultimately lead. A fascinating conversation about regenerative medicine, biotechnology, entrepreneurship, and the possibility of changing how damaged human tissue is treated. dpbioinnovations.com
Neuraura with CEO Claire Dixon
2026/10/02
Claire Dixon, Neuraura: Neural Sensing, Stimulation and the Future of Bioelectronics In this episode of Investment Research Radio, I sit down with Claire Dixon, CEO and Co-Founder of Neuraura, to explore the technology behind the company's next generation approach to neural sensing and stimulation. Neuraura is developing advanced microelectrode technology designed to both record neural activity and stimulate neural tissue, opening potential applications that go beyond conventional sensing technologies. We discuss the origins of Neuraura, its connection to the University of Calgary and the research that led to the company's technology, as well as the journey from academic research to commercial development. Claire explains the technology behind Neuraura's microelectrodes, including the importance of the interface between the technology and the body, and how sensing and stimulation could potentially be combined to create new approaches to monitoring and treatment. We also discuss LoOoP by Neuraura, the company's work in women's health and PCOS, the broader applications of its underlying technology, clinical development, regulatory considerations and the company's vision for the future. The conversation also covers Neuraura's financing journey, including early investment, non-dilutive funding and the capital required to advance its technology toward clinical validation and commercialization. In this episode we discuss: • Claire Dixon's background and the origins of Neuraura • The University of Calgary research behind the technology • Neuraura's microelectrode technology • Neural sensing and neural stimulation • Why the technology goes beyond conventional sensors • The potential for closed loop sensing and stimulation • Microneedle and minimally invasive approaches • LoOoP by Neuraura and women's health • PCOS/PMOS and the company's current focus • Potential applications beyond the company's current products • Clinical development and regulatory pathways • Neuraura's major milestones • The company's financing history and use of capital • Future financing and development milestones • Partnerships and commercialization • Claire's vision for Neuraura    neuraura.com
Regulify.ai with Founder and CEO Kundan Krishna
2026/09/29
In this episode of Investment Research Radio, we explore Regulify, an AI powered platform designed to help MedTech companies navigate the complex regulatory, quality, risk and product development processes required to bring medical devices to market. Regulify goes beyond simply adding AI to an existing software system. The platform is designed as an intelligence layer connecting regulatory, quality, product development, risk, clinical evidence and other critical functions across the MedTech product lifecycle. We discuss why traditional regulatory and quality workflows can be fragmented, how Regulify works alongside existing eQMS platforms, and how its AI driven approach can help companies manage changes, identify regulatory requirements, streamline documentation and potentially reduce the time and resources required to bring products to market. We also explore Regulify's competitive landscape, the technology behind the platform, its potential to change how MedTech companies manage their regulatory and quality infrastructure, and what could make the platform difficult to replicate. Whether you are a MedTech founder, medical device executive, regulatory professional, investor or strategic partner, this conversation provides an inside look at the growing role of AI in medical device development and regulatory compliance. In this episode we discuss: • The origins of Regulify • The regulatory and quality challenges facing MedTech companies • What Regulify is and how the platform works • Regulify's AI powered intelligence layer • Connecting regulatory, quality, risk, clinical and product development workflows • How Regulify works with existing eQMS platforms • FDA regulatory processes and time to market • The competitive landscape • Regulify's technology and potential defensibility • The future of AI in MedTech regulation and product development Investment Research Radio features conversations with founders, executives and innovators building the companies and technologies shaping the future of healthcare, technology and industry.   regulify.ai
Entirety Bio with CEO Jake Edick
2026/09/22
Jake Edick, Entirety Biomedical: Reinventing Bioabsorbable Implants with Curasorb In this episode of Investment Research Radio, I sit down with Jake Edick, founder of Entirety Biomedical, to explore the future of medical implants and the company's Curasorb platform, a next generation approach to bioabsorbable orthopedic hardware. Traditional permanent implants, including titanium hardware, can provide the structural support surgeons need, but they can also remain in the body long after their job is done. Entirety Biomedical is developing a different approach: implants designed to provide temporary mechanical support and then gradually resorb as the body heals. Jake takes us inside the technology behind Curasorb, including Entirety's work with magnesium and its decision to pursue a non coated magnesium implant. We discuss what differentiates the platform from other bioabsorbable implant technologies and how the company believes its approach could create value for both surgeons and patients. We also discuss the company's regulatory and clinical development pathway, the applications Entirety is pursuing, its commercialization strategy, and the opportunity Jake sees for bioabsorbable implants across orthopedic surgery. Jake recently led Entirety Biomedical through its seed financing, so we also talk about what the company is using the capital to accomplish, the milestones ahead, and what it will take to move from promising technology toward clinical and commercial adoption. In this episode we discuss: • Jake's background in medical devices and biomaterials • The limitations of permanent titanium hardware • The problem Entirety Biomedical was created to solve • The Curasorb bioabsorbable implant platform • Magnesium as an implant material • Why Entirety is developing a non coated magnesium implant • How Curasorb differs from other bioabsorbable technologies • Potential benefits for patients and surgeons • FDA and clinical development milestones • Target applications and commercialization strategy • Entirety Biomedical's recent seed financing • The company's growth plans and upcoming milestones • Jake's five year vision for Entirety Biomedical • The broader opportunity in bioabsorbable medical devices   https://www.entiretybio.com
Graphene Manufacturing Group with CEO Craig Nichol
2026/08/21
Ray Crowley Interviews Craig Nicol, CEO of Graphene Manufacturing Group In this episode of Investment Research Radio, Ray sits down with Craig Nicol, Founder, CEO and Managing Director of Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTC: GMGMF) (Frankfurt: 0GF), to discuss the evolution of GMG from a graphene producer into a vertically integrated advanced materials and energy technology company. The conversation explores five interconnected assets and potential revenue streams built around GMG's proprietary graphene platform: 1. Graphene Raw Material Craig explains GMG's proprietary graphene manufacturing technology and the recent commissioning of its Gen 2.0 production plant, designed to produce up to 10 tonnes of graphene annually once fully optimized. The in-house production capability gives GMG control over material quality, supply and cost while providing the foundation for its downstream products. 2. THERMAL-XR® The discussion then moves to GMG's commercial energy savings business. THERMAL-XR® is a graphene enhanced coating designed to improve heat transfer and protect HVAC and industrial heat exchange equipment. With US EPA approval, North American distribution through Nu-Calgon and record June 2026 sales orders exceeding A$400,000, this represents GMG's most immediate commercial revenue opportunity. 3. G® LUBRICANT Ray and Craig discuss GMG's graphene lubricant additive, designed to reduce friction, fuel consumption and emissions in engines and other industrial applications. GMG has reported independently verified fuel efficiency improvements of up to 8.4% in diesel engine testing. The opportunity is to build recurring product revenue through distributors and industrial customers. 4. SUPA G® Battery Material The fourth layer of the business is GMG's proprietary graphene slurry for lithium ion batteries. Rather than having to manufacture an entire battery, SUPA G® potentially allows GMG to sell a specialized material into existing battery manufacturing supply chains. This creates another pathway to monetize the graphene platform while battery manufacturers evaluate performance improvements. 5. G CELLS™ Graphene Aluminium Ion Battery Finally, the conversation looks at GMG's highest value and longest term opportunity: its graphene aluminium ion battery technology. Developed with the University of Queensland and supported by Australian government funding, the technology is being advanced toward larger cells, manufacturing processes and eventual commercialization. This could ultimately move GMG from selling materials and additives into supplying an entire next generation energy storage technology. Ray and Craig discuss how these five assets create a layered commercialization strategy: produce the raw material, sell graphene enabled products, supply graphene into other manufacturers' batteries, and ultimately develop GMG's own battery technology. The conversation also looks ahead to GMG's expansion into North America and Europe, additional industrial applications, data centre cooling, strategic partnerships and the potential for modular graphene production facilities. Craig explains how the company's near term focus is converting commercial product adoption into revenue while continuing to invest in the much larger battery opportunity. The central investment story is therefore not simply graphene production alone. It is GMG's attempt to build an integrated materials platform where one proprietary graphene manufacturing capability supports multiple products, and multiple revenue streams.
Nuvo Interview With Co-Founder and CEO Laurence Klein
2026/06/09
In this episode, we sit down with Laurence Klein, Co-Founder and CEO of Nuvo, to explore how the FDA cleared INVU™ platform is reshaping maternal fetal surveillance and redefining the standard of care for pregnancy. Laurence traces the company's mission to replace episodic, clinic bound monitoring with continuous, medical grade prenatal care delivered at home or at work — and explains how that vision is now meeting a rapidly expanding commercial market. We cover: The Genesis of Nuvo — How a pregnancy wearable idea became a mission to decentralize prenatal care and put clinical-grade monitoring in the hands of expectant mothers wherever they are. The Biosensing Architecture — How INVU™'s passive array of ECG and PCG surface sensors, paired with cloud-based AI, achieves medical-grade fetal monitoring without active ultrasound — and what that means for accuracy, wearability, and scale. The Market Opportunity — Why the convergence of rural care gaps, urban lifestyle demands, and remote monitoring is creating a structural shift — not just a product category. Capital Strategy & What's Next — Deployment priorities following their Series A, the role of generative data pipelines in expanding clinical intelligence, and what institutional investors should be watching heading into the next growth round. Essential listening for anyone following the intersection of deeptech medical devices, digital health infrastructure, and AI-driven diagnostics.

Podcast reviews

Read Investment Research Radio podcast reviews


0 out of 5
0 reviews

Podcast sponsorship advertising

Start advertising on Investment Research Radio relevant audience podcasts


What do you want to promote?